Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @MedResCol
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @MedResCol
-
Prikvačeni tweet
$AMRN$IBB$XBI@viceroyresearch@Hedgeye@PlainviewLLC@SeligmanRsrch MRC's thesis, "AMRN: Market Headwinds and Inherent Weakness of the Vascepa IP" is now publicly accessible both on our website (free purchase): https://medicalresearchcollaborative.com/reports?product_id=51 … and SCRIBD:https://www.scribd.com/document/440390979/AMRN-Market-Headwinds-and-Inherent-Weakness-of-the-Vascepa-IP …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
during this time, the XBI, IBB, and SPX have gained approximately 5.5%, 4.3%, and 4.4%, respectively. The "MRC Fund" is >25% weighted short-AMRN, with a basis of $21.44. A further ~5% is leveraged in June expiry put options, for an approximate 30% total weighting.
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Because we're expecting
$AMRN to crash from this point forward, netting outsized returns for the "MRC Fund," it seems like a good point to update how this has been tracking. As of today, The MRC Fund is currently up 19.70% from the date we began publicly disseminating our book;Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The
@Jefferies notes continue to be rubbish. Now they are attempting to relay “reads” on the Defense (of course in a bullish manner), and hoping the fewer attorneys vs at beginning of trial means a favorable settlement looming. When$AMRN loses, don’t forget to re-read these.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
If ANDA labels are not found to induce infringement of the “12-weeks” limitation, OR the “Other Health Benefits” claims, the case is dead and ruled in favor of DRL/Hikma. And that’s very likely to happen. You should consider our latest analysis: https://medicalresearchcollaborative.com/reports?product_id=59 …
$AMRNPrikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
already found this to be true (see below). The only reason the patents were allowed by the examiner was due to secondary considerations, not the content of claim 1 of the ‘929 patent.pic.twitter.com/b2k3Ebv8Of
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
and what is left are or are not then found infringed (direct or induced). Claim 16 of the ‘728 patent was disclosed in the batch analyses of Epadel manufactured pre-2008 (99.8% pure). That’s an easy delete. What about claim 1 of the ‘929 patent? Clearly obvious. The examiner
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
It’s a rudimentary matter to show that because claim 16 of the ‘728 patent and claim 1 of the ‘929 are invalid as obvious, that therefore there can be no induced infringement of these claims. And the order in Hatch-Wax trials goes this way: all claims found invalid are stricken,
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
It is already invalid as obvious. Technically, this is also true of claim 16 of the ‘728 patent. See both patents’ claims asserted at trial below:pic.twitter.com/UQOdQHj3xt
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
HDGabor is correct that the “Other Health Benefits” claims on LDL-C and apoB are not present in claim@1 of the ‘929 patent. Thus, if there is no inducement of the Other Health Benefits claims, claim 1 of the ‘929 patent, *could* be infringed for other reasons. Unless..
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$AMRN HDGabor has made some adjustments in his latest overview, and it’s much better now. He also points out an admission by us, which is correct. But, there’s a big problem... Let’s take a look: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=153490619 …pic.twitter.com/eYDTWF6Pup
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Amarin is not arguing that ANDA labels show intent to induce infringement of the “12-weeks” limitation at all (its clearly obvious), but rather the “without increasing LDL-C” and “to effect a decrease in apoB” mentions in asserted claims. Our analysis above covers this ground.
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$AMRN And here’s an “overview” of inducement charge by “HDGabor.” But he actually only mentions one of Defendants’ (weakest) arguments against inducement, and doesn’t cite the charge correctly at all:pic.twitter.com/tGcb4GNa3N
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Here’s a good example of the complexity here. “Ortakoy,” a purported attorney that posts on Ihub, cited a portion of Bayer that actually *substantiates* Defendants’ case for non-inducement, without even realizing he did so: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=153375083 …pic.twitter.com/OiUoR98mNX
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$CVM This “clever” wording (pic below) means that like the DCVax-L P3, the “IT-MATTERS” trial is unlikely to ever end. They don’t even want you to know the name of the trial: https://clinicaltrials.gov/ct2/show/NCT01265849 …pic.twitter.com/Nn6GPY7J0K
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$AMRN Do you know what is one of the more interesting aspects of this case? Expert testimony on inducement is almost completely irrelevant.Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
MRC's comprehensive analysis on inducement based on trial proceedings to date, including critique of Amarin's Proposed Findings of Fact and Conclusions of Law, is now available for sale on our website (below): https://medicalresearchcollaborative.com/reports?product_id=59 …
$AMRN$IBB$XBI$SPY$MTNBPrikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
I really do appreciate
@HCWCO pumping this thing on pure air. Sudden liquidity, lovely double digit short entries, hopium. Thanks.Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Added substantially to
$CVM short between $13.50-$13.80, now average ~$12.20. No more adds; sitting pat.Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.